Atherogenic dyslipidemia in patients with established coronary artery disease

Nutrition, Metabolism and Cardiovascular Diseases

Volumn 22, Issue 2, 2012, Pages 103-108

  Lahoz, C ^a   Mostaza, J M ^a   Tranche, S ^b   Martin Jadraque, R ^a   Mantilla, M T ^c   Lopez Rodriguez I ^d   Monteiro, B ^e   Sanchez Zamorano, M A ^e   Taboada, M ^f  

^a HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^b Centro de Salud El Cristo   (Spain)

^c Centro de Salud Mar Baltico   (Spain)

^d Centro de Salud de Begonte   (Spain)

^e Cardiovascular Department   (Spain)

^f Centro de Salud Fuencarral   (Spain)

Author keywords

Atherogenic dyslipidemia; Coronary disease; HDL cholesterol; Triglycerides

Indexed keywords

ANTILIPEMIC AGENT; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL;

AGED; ARTICLE; ATHEROSCLEROSIS; BLOOD; BODY MASS; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDY; DYSLIPIDEMIA; FEMALE; HUMAN; MALE; MIDDLE AGED; PREVALENCE;

AGED; ATHEROSCLEROSIS; BODY MASS INDEX; CHOLESTEROL, HDL; CHOLESTEROL, LDL; CORONARY ARTERY DISEASE; CROSS-SECTIONAL STUDIES; DYSLIPIDEMIAS; FEMALE; HUMANS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; PREVALENCE; TRIGLYCERIDES;

EID: 84856589202     PISSN: 09394753     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.numecd.2010.04.010     Document Type: Article

References (19)

1. Fruchart J.C., Sacks F., Hermans M.P., Assmann G., Brown W.V., Ceska R., et al. The residual risk reduction initiative: a call to action to reduce residual vascular risk in patients with dyslipidemia. Am J Cardiol 2008, 102:1K-34K.
2. Grundy S.M. Atherogenic dyslipidemia: lipoprotein abnormalities and implications for therapy. Am J Cardiol 1995, 75:45B-52B.
3. Ballantyne C.M., Olsson A.G., Cook T.J., Mercuri M.F., Pedersen T.R., Kjekshus J. Influence of low high-density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation 2001, 104:3046-3051.
4. Austin M.A., Rodriguez B.L., McKnight B., McNeely M.J., Edwards K.L., Curb J.D., et al. Low-density lipoprotein particle size, triglycerides, and high-density lipoprotein cholesterol as risk factors for coronary heart disease in older Japanese-American men. Am J Cardiol 2000, 86:412-416.
5. Assmann G., Schulte H. Relation of high-density lipoprotein cholesterol and triglycerides to incidence of atherosclerotic coronary artery disease (the PROCAM experience). Prospective Cardiovascular Munster study. Am J Cardiol 1992, 70:733-737.
6. Manninen V., Tenkanen L., Koskinen P., Huttunen J.K., Manttari M., Heinonen O.P., et al. Joint effects of serum triglyceride and LDL cholesterol and HDL cholesterol concentrations on coronary heart disease risk in the Helsinki Heart Study. Implications for treatment. Circulation 1992, 85:37-45.
7. Brunzell J.D., Davidson M., Furberg C.D., Goldberg R.B., Howard B.V., Stein J.H., et al. Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation. Diabetes Care 2008, 31:811-822.
8. Adiels M., Olofsson S.O., Taskinen M.R., Boren J. Diabetic dyslipidaemia. Curr Opin Lipidol 2006, 17:238-246.
9. Alsheikh-Ali A.A., Lin J.L., Abourjaily P., Ahearn D., Kuvin J.T., Karas R.H. Prevalence of low high-density lipoprotein cholesterol in patients with documented coronary heart disease or risk equivalent and controlled low-density lipoprotein cholesterol. Am J Cardiol 2007, 100:1499-1501.
10. Girman C.J., Rhodes T., Mercuri M., Pyorala K., Kjekshus J., Pedersen T.R., et al. The metabolic syndrome and risk of major coronary events in the Scandinavian Simvastatin Survival Study (4S) and the Air Force/Texas Coronary Atherosclerosis Prevention Study (AFCAPS/TexCAPS). Am J Cardiol 2004, 93:136-141.
11. Ninomiya J.K., L'Italien G., Criqui M.H., Whyte J.L., Gamst A., Chen R.S. Association of the metabolic syndrome with history of myocardial infarction and stroke in the Third National Health and Nutrition Examination Survey. Circulation 2004, 109:42-46.
12. Arca M., Montali A., Valiante S., Campagna F., Pigna G., Paoletti V., et al. Usefulness of atherogenic dyslipidemia for predicting cardiovascular risk in patients with angiographically defined coronary artery disease. Am J Cardiol 2007, 100:1511-1516.
13. Belsey J., de L.S., Chan T., van V.J., Hague N. Abnormal lipids in high-risk patients achieving cholesterol targets: a cross-sectional study of routinely collected UK general practice data. Curr Med Res Opin 2008, 24:2551-2560.
14. Lahoz C., Mostaza J.M., Mantilla M.T., Taboada M., Tranche S., Lopez-Rodriguez I., et al. Achievement of therapeutic goals and utilization of evidence-based cardiovascular therapies in coronary heart disease patients with chronic kidney disease. Am J Cardiol 2008, 101:1098-1102.
15. Mostaza-Prieto J.M., Martin-Jadraque L., Lopez I., Tranche S., Lahoz C., Taboada M., et al. Evidence-based cardiovascular therapies and achievement of therapeutic goals in diabetic patients with coronary heart disease attended in primary care. Am Heart J 2006, 152:1064-1070.
16. Executive summary of the third report of The National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001, 285:2486-2497.
17. Levey A.S., Bosch J.P., Lewis J.B., Greene T., Rogers N., Roth D. A more accurate method to estimate glomerular filtration rate from serum creatinine: a new prediction equation. Modification of Diet in Renal Disease Study Group. Ann Intern Med 1999, 130:461-470.
18. Bruckert E., Baccara-Dinet M., McCoy F., Chapman J. High prevalence of low HDL-cholesterol in a pan-European survey of 8545 dyslipidaemic patients. Curr Med Res Opin 2005, 21:1927-1934.
19. Secondary prevention by raising HDL cholesterol and reducing triglycerides in patients with coronary artery disease: the Bezafibrate Infarction Prevention (BIP) Study. Circulation 2000, 102:21-27.